



PHARMACEUTICAL 2023







IKINNATE

н

A R

м

0

Ρ



RealRate

PHARMACEUTICAL 2023

Kinnate Biopharma Inc. Rank 79 of 446



The relative strengths and weaknesses of Kinnate Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kinnate Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Kinnate Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 176% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	230,837
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,167
Liabilities, Non-Current	3,191
Other Assets	44,918
Other Compr. Net Income	-886
Other Expenses	0
Other Liabilities	0
Other Net Income	2,250
Other Revenues	0
Property and Equipment	3,071
Research and Development	88,150
Selling, General and Administrative Expense	30,371

Output Variable	Value in 1000 USD
Assets	278,826
Liabilities	20,358
Expenses	118,521
Revenues	0
Stockholders Equity	258,468
Net Income	-116,271
Comprehensive Net Income	-116,714
Economic Capital Ratio	219%

